Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Brahmajee Nallamothu

Interventional Cardiology · UMHS

View

Dr. Mohamad Adnan Alkhouli

Interventional Cardiology · Mayo Clinic College of Medicine

View

Dr. Ajay Kirtane

Interventional Cardiology · CUIMC

View

Dr. Manesh Patel

Interventional Cardiology · Duke University

View

Dr. Deepak Bhatt

Interventional Cardiology · Mount Sinai

View

Dr. Sunil Rao

Interventional Cardiology · NYU Langone

View

Dr. Alexander Fanaroff

Interventional Cardiology · UPenn

View

Dr. James Tcheng

Interventional Cardiology · Duke

View

Dr. Pinak Shah

Interventional Cardiology · PHS

View

Dr. Dorairaj Prabhakaran

General Cardiology

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Adenosine Contrast Correlations in Evaluating Revascularization: The (ACCELERATION) Study.

    Apr 24, 2025DOI: 10.1161/circinterventions.125.015240Journal ArticleAHA

    Written by: Rajesh V SwaminathanGuillaume Marquis-GravelLaurie-Anne Boivin-ProulxDaniel K BenjaminAruna RikhiGanesh RaveendranJeff W ChambersArnold H SetoJayant BagaiRoseann WhiteJorge Antonio GutierrezThomas J PovsicSunil V RaoMitchell W Krucoff

    Find these authors on Roon

    GR
    Dr. Ganesh Raveendran
    Interventional Cardiology · University of Minnesota

    Summary

    BACKGROUND: Injection of contrast media for rapid measurement of contrast fractional flow reserve (cFFR) obviates the side effects and time requirements of adenosine fractional flow reserve (aFFR) and improves diagnostic performance relative to nonhyperemic pressure ratios. However, studies of cFFR have had variable delivery of contrast. We evaluated the diagnostic performance of cFFR using an automated contrast injector with a standardized volume and rate of delivery of contrast to the reference standard aFFR.METHODS: The ACCELERATION study (Adenosine Contrast Correlations in Evaluating Revascularization) is an investigator-initiated, multicenter, prospective, single-arm trial conducted in 5 sites across the United States. cFFR and aFFR were measured in patients with stable coronary artery disease and intermediate stenosis (40% to 70%) using the ACIST CVi automated contrast injector (iopamidol; left coronary: rate of 4 mL/s, volume of 10 cm3 and right coronary: rate of 3 mL/s, volume of 6 cm3) and RXi/Navvus FFR microcatheter. The diagnostic performance of cFFR was assessed using a 0.83 cutoff value based on published literature. Optimal cFFR cutoffs were also determined and illustrated using Bland-Altman analysis.RESULTS: A total of 192 lesions from 178 patients were included in the per-protocol analysis (69 with an aFFR ≤0.80 and 109 with an aFFR >0.80). Using a cFFR cutoff value of ≤0.83, the accuracy, sensitivity, and specificity of cFFR were 0.89 (95% CI, 0.83-0.93), 0.70 (95% CI, 0.58-0.81), and 0.99 (95% CI, 0.95-1.00), respectively. The mean difference between cFFR and aFFR was 0.05 (-0.04 to 0.13). A cFFR threshold of ≤0.85 had the highest accuracy in predicting aFFR ≤0.80 with accuracy, sensitivity, and specificity equaling 0.90 (95% CI, 0.84-0.94), 0.87 (95% CI, 0.77-0.94), and 0.91 (95% CI, 0.84-0.95), respectively.CONCLUSIONS: cFFR utilizing standardized parameters for contrast delivery leads to clinically acceptable levels of diagnostic performance compared with traditional aFFR to identify physiologically significant intermediate lesions. Future data evaluating the impact on clinical outcomes of cFFR-guided percutaneous coronary intervention are warranted.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03557385.
    GR

    Dr. Ganesh Raveendran

    Cardiology · Interventional Cardiology
    University of Minnesota
    ganeshan